<DOC>
	<DOC>NCT00942864</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).</brief_summary>
	<brief_title>Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed written informed consent Patients with macular edema due to RVO (confirmed by fundus photography, fluorescein angiography, OCT) Male and female aged from 18 to 70 Baseline bestcorrected visual acuity (BCVA) in the study eye was from 20/400 to 20/30 using ETDRS chart Additional eye disease that could compromise VA Ocular inflammation Intraocular surgery ≤ 1 month before day 0 Uncontrolled glaucoma Prior treatments with laser photocoagulation or other intervention for macular edema due to BRVO Patients aged under 18 or over 71 Female patient in pregnancy or breast feeding Not suitable to regular follow up</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>